A Phase IV, Prospective, Open-label, Multicentre, Single Arm, 3-month Proof of Concept Study to Assess the Effect of IKERVIS® Eye Drops Administered Once Daily on the Quality of Vision in Dry Eye Disease (DED) Patients With Severe Keratitis

Trial Profile

A Phase IV, Prospective, Open-label, Multicentre, Single Arm, 3-month Proof of Concept Study to Assess the Effect of IKERVIS® Eye Drops Administered Once Daily on the Quality of Vision in Dry Eye Disease (DED) Patients With Severe Keratitis

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 13 Oct 2017

At a glance

  • Drugs Ciclosporin (Primary)
  • Indications Dry eyes
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Santen S.A.S.
  • Most Recent Events

    • 04 Oct 2017 Planned End Date changed from 1 Jan 2018 to 1 Jul 2018.
    • 04 Oct 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Jul 2018.
    • 12 Jan 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top